De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Larimar Therapeutics Beheer

Beheer criteriumcontroles 2/4

De CEO Larimar Therapeutics' is Carole Ben-Maimon, benoemd in May2020, heeft een ambtstermijn van 4.42 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 3.14M, bestaande uit 17.8% salaris en 82.2% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.18% van de aandelen van het bedrijf, ter waarde $ 740.66K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.3 jaar en 4.2 jaar.

Belangrijke informatie

Carole Ben-Maimon

Algemeen directeur

US$3.1m

Totale compensatie

Percentage CEO-salaris	17.8%
Dienstverband CEO	4.4yrs
Eigendom CEO	0.2%
Management gemiddelde ambtstermijn	4.3yrs
Gemiddelde ambtstermijn bestuur	4.2yrs

Recente managementupdates

Recent updates

Larimar Therapeutics (NASDAQ:LRMR) Is In A Good Position To Deliver On Growth Plans

Aug 09

Larimar Therapeutics: More Data Still Needed

Jul 15

Larimar: Stronger Buy Now More Than Ever After Partial Clinical Hold Completely Removed

May 31

We're Hopeful That Larimar Therapeutics (NASDAQ:LRMR) Will Use Its Cash Wisely

Nov 13

Here's Why We're Not Too Worried About Larimar Therapeutics' (NASDAQ:LRMR) Cash Burn Situation

May 19

Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth

Feb 02

Laramar Therapeutics issued patent for lead pipeline candidate

Oct 20

Larimar Therapeutics prices ~$70M stock offering

Sep 14

Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Deliver On Growth Plans?

Sep 02

Larimar Therapeutics GAAP EPS of -$0.47

Aug 11

We Think Larimar Therapeutics (NASDAQ:LRMR) Needs To Drive Business Growth Carefully

Mar 21

Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Invest In Growth?

Dec 18

Larimar under pressure as FDA puts clinical hold on CTI-1601 program

May 26

Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth

Feb 08

Analyse CEO-vergoeding

Hoe is Carole Ben-Maimon's beloning veranderd ten opzichte van Larimar Therapeutics's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$58m
Mar 31 2024	n/a	n/a	-US$45m
Dec 31 2023	US$3m	US$560k	-US$37m
Sep 30 2023	n/a	n/a	-US$33m
Jun 30 2023	n/a	n/a	-US$33m
Mar 31 2023	n/a	n/a	-US$33m
Dec 31 2022	US$2m	US$528k	-US$35m
Sep 30 2022	n/a	n/a	-US$35m
Jun 30 2022	n/a	n/a	-US$44m
Mar 31 2022	n/a	n/a	-US$47m
Dec 31 2021	US$2m	US$510k	-US$51m
Sep 30 2021	n/a	n/a	-US$56m
Jun 30 2021	n/a	n/a	-US$49m
Mar 31 2021	n/a	n/a	-US$48m
Dec 31 2020	US$5m	US$268k	-US$42m

Compensatie versus markt: De totale vergoeding ($USD 3.14M ) Carole } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 2.40M ).

Compensatie versus inkomsten: De vergoeding van Carole is gestegen terwijl het bedrijf verliesgevend is.

CEO

Carole Ben-Maimon (65 yo)

4.4yrs

Tenure

US$3,137,432

Compensatie

Dr. Carole S. Ben-Maimon, M.D., is President, Chief Executive Officer and Director at Larimar Therapeutics, Inc. since May 28, 2020. She was Chief Executive Officer, President and Director at Chondrial The...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Carole Ben-Maimon	CEO, President & Director	4.4yrs	US$3.14m	0.18% $ 709.0k
Michael Celano	Secretary & CFO	4.4yrs	US$1.42m	0.087% $ 349.5k
Gopi Shankar	Chief Development Officer	1.7yrs	US$1.43m	0.0078% $ 31.4k
John Berman	Vice President of Finance & Administration	1.2yrs	geen gegevens	geen gegevens
Jennifer Johansson	Vice President of Legal & Compliance	7.8yrs	geen gegevens	geen gegevens
Russell Clayton	Chief Medical Officer	1.3yrs	geen gegevens	geen gegevens
Francis Conway	VP & Controller	4.3yrs	geen gegevens	geen gegevens

4.3yrs

Gemiddelde duur

64yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van LRMR wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.3 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Carole Ben-Maimon	CEO, President & Director	4.4yrs	US$3.14m	0.18% $ 709.0k
Jonathan Leff	Independent Director	4.4yrs	US$79.96k	geen gegevens
Jeffrey Sherman	Independent Director	less than a year	US$56.43k	0% $ 0
Frank Thomas	Independent Director	10.3yrs	US$86.21k	0.0031% $ 12.5k
Thomas Hamilton	Independent Director	4.4yrs	US$77.77k	0.89% $ 3.5m
Joseph Truitt	Independent Chairman of the Board	4.4yrs	US$114.96k	0.0043% $ 17.2k
Giovanni Manfredi	Member of Scientific Advisory Board	4yrs	geen gegevens	geen gegevens
Mark Payne	Member of Scientific Advisory Board	4yrs	geen gegevens	geen gegevens
Marni Falk	Member of Scientific Advisory Board	4yrs	geen gegevens	geen gegevens
Jill Ostrem	Member of Scientific Advisory Board	2.1yrs	geen gegevens	geen gegevens

4.2yrs

Gemiddelde duur

57.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van LRMR wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.2 jaar).

Larimar Therapeutics Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Larimar Therapeutics, Inc. Appoints Dr. Jeffery W. Sherman to its Board of Directors

Larimar Therapeutics, Inc. Announces Chief Medical Officer Changes

Larimar Therapeutics, Inc. Appoints Gopi Shankar as Chief Development Officer

High number of new and inexperienced directors

CEO, President & Director recently bought US$100k worth of stock

High number of new and inexperienced directors

Recent updates

Larimar Therapeutics, Inc. Announces Data from the Nomlabofusp Phase 1 Studies and Phase 2 Dose Exploration Study

Larimar Therapeutics (NASDAQ:LRMR) Is In A Good Position To Deliver On Growth Plans

Larimar Therapeutics: More Data Still Needed

Larimar Therapeutics, Inc.(NasdaqGM:LRMR) dropped from Russell Small Cap Comp Value Index

Larimar: Stronger Buy Now More Than Ever After Partial Clinical Hold Completely Removed

United States Food and Drug Administration Selects Larimar Therapeutics, Inc. to Participate in Start Pilot Program for Nomlabofusp in Friedreich's Ataxia

Larimar Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

New major risk - Revenue and earnings growth

Larimar Therapeutics Announces the Dosing of the First Patient in Long-Term Open Label Extension Study for Nomlabofusp in Patients with Friedreich’S Ataxia

New minor risk - Shareholder dilution

Larimar Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $150.000005 million.

Larimar Therapeutics, Inc. has withdrawn its Follow-on Equity Offering in the amount of $50 million.

Price target increased by 41% to US$16.24

Larimar Therapeutics, Inc. Reports Positive Top-Line Data from Phase 2 Dose Exploration Study from 25 Mg and 50 Mg Cohorts of Nomlabofusp in Patients with Friedreich's Ataxia

We're Hopeful That Larimar Therapeutics (NASDAQ:LRMR) Will Use Its Cash Wisely

Larimar Therapeutics, Inc. Appoints Dr. Jeffery W. Sherman to its Board of Directors

Larimar Therapeutics Receives FDA Clearance to Proceed to 50 mg Cohort in CTI-1601's Phase 2 Friedreich's Ataxia Trial

Larimar Therapeutics, Inc. Announces Chief Medical Officer Changes

Here's Why We're Not Too Worried About Larimar Therapeutics' (NASDAQ:LRMR) Cash Burn Situation

Larimar Therapeutics Reports Preliminary Top-Line Data from Phase 2 Trial’S 25 Mg Cohort Showing Increases in Frataxin Levels in Patients with Friedreich’S Ataxia

Larimar Therapeutics, Inc. Appoints Gopi Shankar as Chief Development Officer

Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth

Price target decreased to US$10.59

High number of new and inexperienced directors

Laramar Therapeutics issued patent for lead pipeline candidate

CEO, President & Director recently bought US$100k worth of stock

Larimar Therapeutics Announces FDA Clearance to Initiate the 25 mg Cohort of a Phase 2 Dose Exploration Trial of CTI-1601 in Friedreich’s Ataxia Patients

Larimar Therapeutics prices ~$70M stock offering

Price target increased to US$6.23

Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Deliver On Growth Plans?

Larimar Therapeutics, Inc. Provides Updates on CTI-1601 Clinical Program Following A Type C Meeting with the U.S. Food and Drug Administration

Larimar Therapeutics GAAP EPS of -$0.47

Price target increased to US$5.88

High number of new and inexperienced directors

Larimar Therapeutics, Inc., Annual General Meeting, May 10, 2022

Larimar Therapeutics, Inc. Announces Not Stand for Re-Election of Thomas O. Daniel as Board of Director

We Think Larimar Therapeutics (NASDAQ:LRMR) Needs To Drive Business Growth Carefully

Price target decreased to US$13.50

Larimar Therapeutics, Inc. Provides Update on CTI-1601 Clinical Program

Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Invest In Growth?

Independent Director recently bought US$496k worth of stock

Larimar Therapeutics, Inc. Reports FDA Clinical Hold on CTI-1601

Larimar under pressure as FDA puts clinical hold on CTI-1601 program

Larimar Therapeutics, Inc. announced that it expects to receive $95.273757 million in funding from Deerfield Management Company, L.P. and other investors

Larimar Therapeutics, Inc. Receives European Medicines Agency Priority Medicines (PRIME) Designation for CTI-1601 in Friedreich’s Ataxia

Larimar Therapeutics Reports Positive Topline Phase 1 Clinical Trial Data Showing Dose-Dependent Increases in Frataxin Levels in Patients with Friedreich’s Ataxia

Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth

New 90-day low: US$17.75

Larimar, Avadel, Applied Therapeutics will added to Nasdaq Biotechnology Index

Larimar Therapeutics Announces Completion of Dosing of the Single Ascending Dose Clinical Trial in Friedreich’s Ataxia Patients and Provides Program Update

Larimar completes dosing in Friedreich’s Ataxia, provides program update

Larimar Therapeutics (LRMR) Investor Presentation - Slideshow

New 90-day high: US$22.50

Larimar Therapeutics reports Q3 results

Larimar Therapeutics Announces Formation of Scientific Advisory Board

New 90-day high: US$18.91

New 90-day high - US$16.00

Larimar Therapeutics, Inc.(NasdaqGM:LRMR) dropped from Russell Microcap Value Index

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd